Jessica Fye

Brandon Folkes

Alex [indiscernible]

Eduardo Martinez-Montes

Raghuram Selvaraju

Yi Chen

- Emergent BioSolutions Inc. received a contract modification valued at **$56 million** from the U.S. government for the supply of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live).  **[1367644_0001367644-25-000188_a09092025acam2000pressrele.htm:0]** **[1367644_0001367644-25-000188_ebs-20250905.htm:1]** 
- Deliveries under this modification are expected to commence in **September 2025** and must be completed by **December 31, 2025**.  **[1367644_0001367644-25-000188_a09092025acam2000pressrele.htm:0]** **[1367644_0001367644-25-000188_ebs-20250905.htm:1]** 
- This new modification contributes to the total projected sales for ACAM2000® vaccine and ancillary products, which are anticipated to exceed **$120 million** this year from various customers.  **[1367644_0001367644-25-000188_a09092025acam2000pressrele.htm:0]**

Emergent BioSolutions (EBS)